Primary Prevention of Coronary Artery Disease. Raj Thaman Consultant Cardiologist Wrexham Maelor
|
|
- Catherine Wilkins
- 7 years ago
- Views:
Transcription
1 Primary Prevention of Coronary Artery Disease Raj Thaman Consultant Cardiologist Wrexham Maelor
2 Objectives Define primary prevention and discuss why primary prevention is necessary. review current approaches to primary prevention Discuss the limitations of the Framingham Risk Assessment model and others additional methods of refining risk stratification Review the evidence base for earlier and more aggressive treatment of hypercholesterolemia
3 Primary prevention of CVD Refers to interventions that aim to prevent or delay the onset of cardiovascular disease in people who have no clinical evidence of CVD (MeSH definition)
4 33% of deaths in the UK are caused by cardiovascular disease Men Causes of death in the UK Women CVD: cardiovascular disease; CHD: coronary heart disease Coronary Heart Disease Statistics, British Heart Foundation: London. Last accessed August 2011.
5 There are regional variations in mortality from cardiovascular disease Deaths from CVD in the UK Males Females Regional variations exist in the incidence of CVD, with Scotland showing the highest rates for men and women CVD: cardiovascular disease Coronary Heart Disease Statistics, British Heart Foundation: London. Last accessed August 2011.
6 What is responsible for reduction in mortality 50% of decline in CVD mortality is due to earlier diagnosis and more aggressive treatment 50%changes in risk factor profiles, decline in smoking, more aggressive management of BP and lipids
7 CVD (CHD, CVD, PVD) is the single most common cause of death in the UK Almost 30% (67,000) of the deaths can be classified as premature (that is, they occurred before the age of 75 years) (equates to 35% and 27% of all premature deaths in men and women) CVD is also a significant cause of morbidity and can have a major impact on quality of life. (In US it is estimated that the cost of treating coronary artery disease will rise to more than $1 trillion annually by 2030, thus prevention is needed)
8 Cardiovascular disease is associated with high healthcare costs Breakdown of healthcare costs associated with cardiovascular disease Medications 20% Primary care 6% Outpatient care 2% Accident and emergency care 0.5% Inpatient care 72% Cardiovascular disease cost the UK healthcare system approximately 14.4 billion in 2006 Adapted from Coronary Heart Disease Statistics, British Heart Foundation: London. Last accessed August 2011.
9 Primary prevention of CHD The fundamental principle in primary prevention of Coronary Heart Disease is the identification of individuals with coronary risk factors and modify those risk factors
10 Modifiable factors increase the risk of myocardial infarction (MI) Abnormal lipids Diabetes Abdominal obesity Inadequate consumption of fruit and vegetables Lack of regular physical exercise Smoking Hypertension Psychosocial factors Excess alcohol Case control study of acute MI in 52 countries Nine risk factors account for >90% of the population attributable risk of MI MI: myocardial infarction Yusuf S, et al. Lancet. 2004; 364:
11 Abnormal lipids and current smoking status are associated with the highest risk of developing acute myocardial infarction Odds ratios for risk factors most associated with the development of acute myocardial infarction *Lipid profile as measured by apolipoprotein B/apolipoprotein A1 ratio Adapted from Yusuf S, et al. Lancet. 2004; 364:
12 Cumulative incidence of CVD adjusted for the competing risk of death for men and women according to aggregate risk factor (RF) burden at 50 years of age IDEAL RISK FACTOR PROFILE BP 120/80 CHOL <180 NONSMOKER NON DIABETIC Lloyd-Jones, D. M. et al. Circulation 2006;113:
13 Rationale Primary prevention reduces MI and HF, decreases the need for coronary revascularization procedures, and extends and improves QOL Treating hypercholesterolaemia in patients who do have evidence of CHD
14 Principles For primary prevention of cardiovascular disease (CVD), people at risk need to be identified before CVD has become established To assess risk in those likely to be at high risk (for example, people with hypertension) a validated assessment tool is needed that evaluates a range of modifiable and non-modifiable risk factors. Epidaemiological data showing that there is a continuous graded relationship between the total plasma cholesterol concentration and CHD events and mortality
15 Risk Stratification Calculators Framingham Joint British Societies Q Risk ASSIGN (Scotland only)
16 Framingham Major risk factors in asymptomatic individuals: smoking, hypertension, high cholesterol (and various cholesterol fractions). Low HDL, diabetes and age Major RF s (85% of excess risk Obesity, physical inactivity, family history of premature CHD, hypertriglycideaemia, small LDL, increased lipoprotein a, increased serum homocysteine and abnormalities in several coagulation factors (fibrinogen), Insulin resistance
17 Framingham Cardiovascular Risk Calculator For Primary Prevention This calculator should not be used if patient has known CVD or diabetes (already known to be at high risk) Age (30-74) Sex Smoking Status Glucose (normal, impaired, diabetic) Systolic BP LVH on ECG yes/ no Diastolic BP Central Obesity yes/ no Total Cholesterol South Asian Origin yes/ no HDL Cholesterol Family History of CVD (Men ) Total /HDL Ratio Serum TG mmol/l 10-year risk of cardiovascular event is. % Values used should have been recorded <6 months before the date of the risk assessment and before any treatment for hypertension. adjustments as suggested by the Joint British Societies' (JBS2) paper and the JBS Cardiovascular Risk Assessor
18 Advantage of Framingham Risk Estimate: allows calculations over various time periods (4 to 12 years) and for different outcomes: cardiovascular disease, stroke, coronary disease, myocardial infarction and death from either coronary or cardiovascular disease
19 Limitations of Framingham Risk Estimate Age and gender are the predominant factors in risk estimate Life time risk estimate may be more relevant than 10 year estimate Over-estimate risk in low risk populations Overestimates risk in high risk populations (upt o 50%). should not be used in people with pre-existing CVD (coronary heart disease, angina, stroke, TIA, PVD,diabetes, CKD (if estimated GFR < below 60), familial hypercholesterolemia, or in people already taking lipid- lowering medication before a new diagnosis of hypertension Guidelines emphasize coronary event reduction rather than preventing atherosclerosis
20 Joint British Societies (JBS) Published in the BNF and based on JBS guidelines. Based on Framingham data JBS/BNF calculates cardiovascular disease risk, based on the sum of the coronary disease and stroke risks (i.e. not individualised).
21 Q risk 2010: NICE decided it could no longer recommend that the Framingham risk equation be the equation of choice [NICE clinical guideline 67 (reissued in February 2010) ] coincided with the emergence of the QRISK calculator which has been shown to predict risk more accurately The QRISK cardiovascular calculator calculates lifetime risk validated using data from a UK primary care database.
22 Age Sex male/ female Ethnicity Postcode About You Clinical Information Do you smoke at all? Do you have diabetes? Are you on regular steroid tablets? Do you have high blood pressure requiring treatment? Have you had a heart attack, angina, stroke or TIA Has anyone in your immediate family* had angina or a heart attack whilst under 60 Do immediate family* have diabetes? Have you been diagnosed with rheumatoid arthritis? Have you been diagnosed with chronic kidney disease? Have you been diagnosed with atrial fibrillation or irregular heartbeat? Do you have congestive cardiac failure? Do you have hypothyroidism? Do you have liver failure? Cholesterol/HDL ratio: Systolic blood pressure (mmhg): Body mass index Weight (kg):height (cm): Calculate
23 Advantages of Q risk More personalized More risk factors: rh art, AF, renal disease, treated hypertension Takes into account your postcode, areas of deprivation Other ethnic variables At the 10year risk threshold of 20%,the population identified by QRISK2 was at higher risk of a CV event than the population identified by the modified algorithm
24 Are scoring algorithms accurate Risk factors change with age What is the impact of those emerging risk factors or others such as childhood obesity Low absolute risk does not mean low lifetime risk Scores don t take into account severity of risk factors (heavy smoking, marked hypertension) Patients aged over 75 years?? Secondary prevention Most scoring systems underestimate risk
25 Effect of individual RF s on Atherogenesis Each of major RF s Smoking, BP
26 Clinical effectiveness of primary prevention Nurses Health study: 120,000, 20 yrs, women who maintained a desirable body weight, ate healthy diet, exercised regularly, and didn t smoke had an 84% reduction in CVD events (3-5% low risk). Meta analysis of PP trials (including a minority of people with established CVD), found that statin therapy was associated with a reduction in the risk of all cause mortality, fatal and nonfatal MI and the composite outcomes of CHD death, nonfatal MI, fatal or nonfatal stroke and coronary revascularization
27 Study Year Primary prevention trials Number Mean Age M/F LDL Event Reduction MI/CV Death WOSCOPS 1995 Pravastatin AFCAPS/ TEXCAPS 1998 Lovastatin M / % (5 years) 37% (5 years) ASCOT 2003 Atorvastatin / Independent of other predictors of outcome 36% Meta analysis of PP trials (including a minority of people with established CVD), found that statin therapy was associated with a reduction in the risk of all cause mortality, fatal and nonfatal MI and the composite outcomes of CHD death, nonfatal MI, fatal or nonfatal stroke and coronary
28 Are statins effective over a wide range of LDL-C Study population (n=17,802) No history of cardiovascular disease LDL cholesterol < 3.4 mmol/l C-reactive protein (CRP) 2 mg/l Men 50 years Women 60 years Rosuvastatin 20 mg (n=8,901) Placebo (n=8,901) monthly Final 3 4 years Run in/eligibility Safety Lipids CRP Safety Median follow-up: 1.9 years Lipids CRP Safety Lipids CRP Safety HbA 1C JUPITER Ridker PM et al. Circulation. 2003; 108: Ridker PM et al. Am J Cardiol. 2007; 100:
29 JUPITER: post-hoc analysis of high-risk subgroup baseline Framingham risk score >20% Cumulative incidence of cardiovascular death/myocardial infarction/stroke Cumulative incidence, % Hazard ratio: 0.50 (95% CI: ) P = NNT 4y = 26 Placebo Rosuvastatin Rosuvastatin Years Placebo Koenig W, Ridker PM. Eur Heart J. 2011; 32:
30 JUPITER: post-hoc analysis of high-risk subgroup baseline Framingham risk score >20% In patients with a baseline Framingham risk score >20% (n=1558 patients), there was: A significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (hazard ratio: 0.5; p=0.028 rosuvastatin vs. placebo) Absolute risk reduction (ARR) in the event rate per 1000 patient-years was 8.8 Total mortality was unchanged (p=0.193) Koenig W, Ridker PM. Eur Heart J. 2011; 32: Crestor. Summary of Product Characteristics. February 2011.
31 Which patients should we intervene on Elevated total cholesterol to HDL cholesterol ratio 6.0 Elevated blood pressure Evidence of atherosclerotic disease All patients Diabetes mellitus and aged over 40 years Diabetes mellitus aged under 40 years and additional risk factors Smoking status Obesity HDL: high density lipoprotein JBS 2. Heart 2005; 91(suppl V): v1-v52. Many factors contribute to cardiovascular risk
32 Risk Catergories Who should receive cardioprotective drugs low: Modify risk (<10%) Cost effectiveness models have not shown benefit of treating low risk patients with generic low intensity statins once adherenace is taken into account Intermediate:??? High: 20% cardioprotective drugs Invasive investigations
33 NICE recommends that patients at risk of cardiovascular events are regularly screened If the person has a history of CHD, angina, stroke or TIA, peripheral vascular disease, diabetes or a monogenic lipid disorder, do not include in risk assessment process as these patients are already considered at high risk Is person 75 or over? Use systematic strategy rather than opportunistic assessment to identify people aged who are likely to be at high risk No Yes Consider at increased risk of CVD, and likely to benefit from statin treatment, particularly if person smokes or has high blood pressure. Consider comorbidities, benefits and risks of treatment, and person s preference Estimate risk using risk factors already recorded in primary care electronic medical records 10-YEAR RISK LESS THAN 20% 10-YEAR RISK 20% OR GREATER Prioritise for full format risk assessment Arrange discussion of risk assessment Review risk on an ongoing basis Discuss process of risk assessment, including option to decline assessment RISK ASSESSMENT DECLINED CHD: coronary heart disease; TIA: transient ischaemic attack; CVD: cardiovascular disease The National Collaborating Centre for Primary Care. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. CG67. Quick reference guide. June Available at: Last accessed August 2011.
34 JBS cont (I) OBJECTIVE OF CVD PREVENTION IN CLINICAL PRACTICE is to reduce the risk of CVD and its complications, including the need for percutaneous or surgical revascularisation procedures in any arterial territory, and to improve quality of life and life expectancy. (II) PRIORITIES FOR CVD PREVENTION IN CLINICAL PRACTICE CVD prevention should focus on all those people who are at high risk, and the following groups of people have equal priority for CVD prevention in clinical practice. People with any form of established atherosclerotic CVD Asymptomatic people without established CVD but who have a combination of risk factors which puts them at high total risk (estimated multifactorial CVD risk 20% over 10 years) of developing atherosclerotic CVD for the first time People with diabetes mellitus (type 1 or 2) In addition, other people with particularly elevated single risk factors also require CVD prevention because they too are at high cardiovascular risk, regardless of the presence of other risk factors: elevated blood pressure 160 mm Hg systolic or 100 mm Hg diastolic, or lesser degrees of blood pressure elevation with target organ damage elevated total cholesterol to high density lipoprotein (HDL) cholesterol ratio 6.0 familial dyslipidaemia People with a family history of premature CVD should be assessed and then managed appropriately
35 Problems with this approach The goal for reducing elevated serum cholesterol in adults is to retard atherogenesis throughout life, not to prevent myocardial infarction in the next decade Reduction of serum cholesterol levels in patients with advanced atherosclerotic disease does not substantially reduce mortality and morbidity from CHD High risk cohorts will have overall relatively few events, most events will occur in those patients at intermediate risk.
36 Can we detect atherogenesis Calcification occurs in most atheroscerotic plaques sub-intimal space Total CAC proportional to total plaque area (CAC makes up about 15-20% of total plaque area) Coronary angiography: luminography Using CT CAC can be visualised within a few seconds at a low radiation exposure
37
38 Quantification of CAC Agatston score (Agatston et al 1990) If there is no CAC can rule out obstructive CAD (0.5%) Acute coronary events can occur in patients with no detectable CAC, eg young smokers Independent risk factor for CV events (park et al 2002) The higher the CAC score the greater the likelihood of MI or cardiovascular death. Independent of CV risk factors (Arad et al) Sensitivity 98% Spec 40% PPV 68% NPP 93% A score >100 more predictive of CV event than traditional RF s
39 Who should be screened with CTCS Asymptomatic patients low risk patients: very few events are expected in these patients so CAC is unlikely to reclassify patients Most high risk patients will remain high risk even with a relatively low CAC score. Intermediate risk patients are more likely to be reclassified In these patients a score >100 would reclassify them as high risk
40 Use of CCS scoring Male>40 years Female >50 years Framingham/ JBS/ Q Risk assessment Low (<10%) Intermediate (10%-20%) High (>20%) Life style modification CCS Scoring Secondary prevention Absent CAC Any CAC
41 Summary Primary prevention is extremely important, clinical and cost implications Patients should be risk stratified whenever possible Risk calculators have their limitations Statins in primary prevention are associated with substantial relative reductions in cardiovascular events Newer technologies may help refine risk stratification in the future
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationAbsolute cardiovascular disease risk assessment
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
More informationPRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationRisk estimation and the prevention of cardiovascular disease. A national clinical guideline
SIGN Scottish Intercollegiate Guidelines Network Help us to improve SIGN guidelines - click here to complete our survey 97 Risk estimation and the prevention of cardiovascular disease A national clinical
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationCoronary Heart Disease (CHD) Brief
Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs
More informationSUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL
SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationInternational Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke
International Task Force for Prevention Of Coronary Heart Disease Clinical management of risk factors of coronary heart disease and stroke Economic analyses of primary prevention of coronary heart disease
More informationBMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.
March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationCohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationFewer people with coronary heart disease are being diagnosed as compared to the expected figures.
JSNA Coronary heart disease 1) Key points 2) Introduction 3) National picture 4) Local picture of CHD prevalence 5) Mortality from coronary heart disease in Suffolk County 6) Trends in mortality rates
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationWill The Coronary Calcium Score Affect the Decision To Treat With Statins?
Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Amresh Raina M.D. Division of Cardiology University of Pennsylvania Disclosures No financial relationships relevant to this presentation
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationStroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
More informationHYPERCHOLESTEROLAEMIA STATIN AND BEYOND
HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause
More informationKDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013
KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE Supplemental Tables November 2013 Suppl Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationMISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY
MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data
More informationUNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s)
UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s) Pilot QOF indicator: The percentage of patients 79
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationHôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationCardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better
Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationThe Canadian Association of Cardiac
Reinventing Cardiac Rehabilitation Outside of acute care institutions, cardiovascular disease is a chronic, inflammatory process; the reduction or elimination of recurrent acute coronary syndromes is a
More informationSummary of QOF indicators
Summary of QOF indicators Clinical domain Atrial fibrillation (AF) AF001. The contractor establishes and maintains a register of patients with atrial fibrillation AF002. The percentage of patients with
More informationAssessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study
European Journal of Clinical Investigation (2007) 37, 925 932 DOI: 10.1111/j.1365-2362.2007.01888.x Blackwell Publishing Ltd Review Assessing risk of myocardial infarction and stroke: new data from the
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationPrimary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing
Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading
More informationAbsolute cardiovascular disease risk management
Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease
More informationRAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 2014
1. 2. RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 214 3.1 Coronary Heart Disease (CHD) 3.2 Heart Failure 1 3.3 Heart Failure 3 (heart failure due to Left Ventricular Systolic Dysfunction) 3.4 Stroke
More informationMultiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden
Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:
More information6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
More informationYour healthcare provider has ordered a Boston Heart Cardiac Risk Assessment
Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationScottish Diabetes Survey 2014. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2014 Scottish Diabetes Survey Monitoring Group Contents Table of Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 21 Duration
More informationChronic diseases in low and middle income countries: more research or more action? Shah Ebrahim London School of Hygiene & Tropical Medicine
Chronic diseases in low and middle income countries: more research or more action? Shah Ebrahim London School of Hygiene & Tropical Medicine More action needed Overview Growing burden of chronic diseases
More informationQuantifying Life expectancy in people with Type 2 diabetes
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
More informationAssociate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland
Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationThe International Agenda for Stroke
1st Global Conference on Healthy Lifestyles and Noncommunicable Diseases Control Moscow, 28-29 April, 2011 The International Agenda for Stroke Marc Fisher MD, University of Massachusetts Editor-in-Chief,
More informationEvidence for Statins in
Evidence for Statins in Secondary & Primary Prevention Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine (Cardiology) Co Director, Prevention Intervention Center University
More informationHypertension Guideline V4
Hypertension Guideline V4 Approved 24/06/2008 Version VERSION 4 FINAL Date of First Issue 26/02/08 Review Date 01/03/2010 Date of Issue 24/06/2008 EQIA Yes / No 24/06/2008 Author / Contact Dr Leslie Cruickshank
More informationCARDIOVASCULAR DISEASE STATISTICS 2014
CARDIOVASCULAR DISEASE STATISTICS 2014 British Heart Foundation Centre on Population Approaches for Non Communicable Disease Prevention. Nuffield Department of Population Health, University of Oxford PREMATURE
More informationOsama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015
STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 PROJECT TITLE: Analysis of ECG Exercise Stress Testing and Framingham Risk Score in Chest Pain Patients PRIMARY SUPERVISOR NAME: Dr. Edward Tan DEPARTMENT:
More informationScottish Diabetes Survey 2013. Scottish Diabetes Survey Monitoring Group
Scottish Diabetes Survey 2013 Scottish Diabetes Survey Monitoring Group Contents Contents... 2 Foreword... 4 Executive Summary... 6 Prevalence... 8 Undiagnosed diabetes... 18 Duration of Diabetes... 18
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationUnderwriting Critical Illness Insurance: A model for coronary heart disease and stroke
Underwriting Critical Illness Insurance: A model for coronary heart disease and stroke Presented to the 6th International Congress on Insurance: Mathematics and Economics. July 2002. Lisbon, Portugal.
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationVascular Risk Reduction: Addressing Vascular Risk
Vascular Risk Reduction: Addressing Vascular Risk Vascular Risk Reduction (VRR) Welcome! Presentation & Activities Focus: Managing known risk factors for vascular disease. Engage, collaborate and have
More informationData, Outcomes and Population Health Management. CPPEG January 2016
Data, Outcomes and Population Health Management CPPEG January 216 NHS Outcomes Framework There are national outcome measures which the CCG is held to account on. In conjunction to monitoring these the
More informationHeartScore Web - based version users guide TABLE OF CONTENTS. 1. Preamble... 2. 2. Benefits of using HeartScore... 2. 3. Accessing HeartScore...
TABLE OF CONTENTS 1. Preamble... 2 2. Benefits of using HeartScore... 2 3. Accessing HeartScore... 2 4. HeartScore Web Based Homepage... 3 5. Patient Card... 4 6. Create a new examination... 6 7. Examination
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationGENERAL HEART DISEASE KNOW THE FACTS
GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to
More informationScottish Diabetes Survey
Scottish Diabetes Survey 2011 Scottish Diabetes Survey Monitoring Group Foreword The Scottish Diabetes Survey 2011 data reflects many aspects of the quality of diabetes care across the whole of Scotland.
More informationStatin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012)
Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Notes relating to this guidance This guidance serves
More informationEUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events
II European Action on Secondary and Primary Prevention through Intervention to Reduce Events Euro Heart Survey Programme European Society of Cardiology-ESC 1 2 Priorities of Coronary Heart Disease Prevention
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationWhat is a Heart Attack? 1,2,3
S What is a Heart Attack? 1,2,3 Heart attacks, otherwise known as myocardial infarctions, are caused when the blood supply to a section of the heart is suddenly disrupted. Without the oxygen supplied by
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationManagement of Lipids in 2015: Just Give them a Statin?
Management of Lipids in 2015: Just Give them a Statin? James H. Stein, M.D. Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Stone NJ, et al. Circulation
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationReview Article. Indian J Med Res 138, October 2013, pp 461-491. Enas A. Enas, Arun Kuruvila, Pravien Khanna, C.S. Pitchumoni * & Viswanathan Mohan **
Review Article Indian J Med Res 138, October 2013, pp 461-491 Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians A population with the highest risk of
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More information4. Does your PCT provide structured education programmes for people with type 2 diabetes?
PCT Prescribing Report Drugs used in Type 2 Diabetes Discussion Points 1. Does your PCT have a strategy for prevention of type 2 diabetes? Does your PCT provide the sort of intensive multifactorial lifestyle
More informationEpidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613
Epidemiology of Hypertension 陈 奕 希 3120000591 李 禾 园 3120000050 王 卓 3120000613 1 Definition Hypertension is a chronic medical condition in which the blood pressure in the arteries is elevated. 2 Primary
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationAbsolute cardiovascular disease risk
Guidelines for the management of Absolute cardiovascular disease risk An initiative of the National Vascular Disease Prevention Alliance About the National Vascular Disease Prevention Alliance The National
More informationThe Relationship Between Low Testosterone and Cardiovascular Disease
Testosterone and Cardiovascular Risk in Men Daniel M. Kelly a T. Hugh Jones a, b a Department of Human Metabolism, Medical School, The University of Sheffield, Sheffield, and b Centre for Diabetes and
More informationAfrican Americans & Cardiovascular Diseases
Statistical Fact Sheet 2013 Update African Americans & Cardiovascular Diseases Cardiovascular Disease (CVD) (ICD/10 codes I00-I99, Q20-Q28) (ICD/9 codes 390-459, 745-747) Among non-hispanic blacks age
More informationCardiovascular Disease Risk Factors
Cardiovascular Disease Risk Factors Risk factors are traits and life-style habits that increase a person's chances of having coronary artery and vascular disease. Some risk factors cannot be changed or
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationECONOMIC COSTS OF PHYSICAL INACTIVITY
ECONOMIC COSTS OF PHYSICAL INACTIVITY This fact sheet highlights the prevalence and health-consequences of physical inactivity and summarises some of the key facts and figures on the economic costs of
More information